🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Georgia

2350 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
NCT07682961HIV Infections
DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361Obesity, Overweight, Chronic Weight Management
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
3,600
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-13
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Recruiting
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
NCT07575269Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
571
Arkansas, Georgia, Iowa, New York, Ohio, Pennsylvania, South Carolina, Texas
2026-07-07
Not yet open
Measuring Knee Laxity and Pivot Shift in ACL-Deficient Patients
NCT07688967Anterior Cruciate Ligament (ACL) Tear
Arthroresearch LLC
Observational
25
Georgia
2026-07-07
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair
NCT07655505Mitral Regurgitation (MR)
Intuitive Surgical
Not applicable
30
Georgia, New York, Washington
2026-07-06
Recruiting
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
NCT07717879ADHD
DrugsSolriamfetol A·Solriamfetol B
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
2,000
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2026-07-06
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
AtaCor Medical, Inc.
Not applicable
280
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky
2026-07-02
Recruiting
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT07453888Non-Arteritic Anterior Ischemic Optic Neuropathy
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Recruiting
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
NCT07426757Advanced Malignancies, Advanced Cancer
DrugMidazolam
Pfizer
Phase 1
120
Florida, Georgia, Tennessee
2026-07-01
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
NCT07536269Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Not yet open
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)
NCT07512128Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002Acute Myeloid Leukemia
DrugsPivekimab Sunirine·Azacitidine·Venetoclax
AbbVie
Phase 2/3
660
California, Florida, Georgia, Missouri, New York, Texas
2026-06-30
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
Boehringer Ingelheim
Phase 2
342
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
NCT07684820Chronic Obstructive Pulmonary Disease (COPD)
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
NCT07489066Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
Safety of MOON101 for the Treatment of Peanut Allergy
NCT07580898Peanut Allergy
Moonlight Therapeutics, Inc.
Phase 1
40
Arkansas, Georgia, Kansas, Michigan, North Carolina
2026-06-29
Recruiting
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT07508787Renal Transplant Failure and Rejection
DrugRabbit anti-thymocyte globulin
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Michigan, New Jersey, Texas, Washington
2026-06-29
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371Moderate-to-Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 3
510
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-06-29
Recruiting
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 3
300
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Michigan
2026-06-26
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
NCT07641517Osteoarthritis, Knee, Chronic Pain
DrugLY4065967
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-06-25
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
DrugsCab Ula·Rpv La·Cab La
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Michigan, Missouri
2026-06-25
Recruiting
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
NCT07717892ADHD
DrugsSolriamfetol A·Solriamfetol B
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-06-25
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597Stomatitis
DrugsDatopotamab deruxtecan·Dato-DXd
AstraZeneca
Phase 4
100
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-06-24
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, North Carolina, Ohio, West Virginia
2026-06-23
Recruiting
Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study
NCT07704060Caregivers, Community Health Workers, Knowledge, Attitude
KDH Research & Communication
Not applicable
360
Georgia
2026-06-19
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
NCT07724340Adults With Overweight/Obesity and Type 2 Diabetes
Antag Therapeutics
Phase 2
150
Arizona, California, Florida, Georgia, Utah
2026-06-19
Recruiting
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
NCT07702578AML, MDS
DrugTSC-101
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
NCT07644052Cannabis Withdrawal
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704Hypercholesterolemia
DrugEvolocumab
Regeneron Pharmaceuticals
Phase 2
420
Alabama, California, Florida, Georgia, Hawaii, Kentucky, Louisiana, Montana
2026-06-17
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896Graves' Disease
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsATRA·Arsenic Trioxide
Quetzal Therapeutics
Phase 3
150
Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2026-06-08
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugGnP
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, North Carolina
2026-06-05
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy
DrugHBS-301
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
NCT07566286Chin Augmentation
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885Psoriasis
DrugD-2570
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
NCT07661329Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Recruiting
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227350Locally Advanced Basal Cell Carcinoma
DrugsL19IL2·L19TNF·L19IL2/L19TNF
Philogen S.p.A.
Phase 2
180
Florida, Georgia, North Carolina, Ohio, Texas
2026-06-01
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
NCT07592273Diabetic Retinopathy
DrugSurabgene Lomparvovec
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06
Not yet open
Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).
NCT07613281Snoring, OSA - Obstructive Sleep Apnea
Serene Sleep, Inc.
Not applicable
26
California, Georgia
2026-06
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
DrugsEnfortumab Vedotin·Pembrolizumab
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsJNJ-79635322·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugTARA-002
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
Recruiting
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
NCT07598708Narcolepsy Type 1, Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina
2026-05-29
Recruiting
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
NCT07610278Hypercholesterolaemia
DrugsQCZ484·Inclisiran
Novartis Pharmaceuticals
Phase 2
120
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-29
Recruiting
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
NCT07629440Pneumococcal Disease
DrugsPG4·20-valent pneumococcal conjugate vaccine
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, New Jersey, New York, Ohio, Texas
2026-05-27
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266Polycythemia Vera
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Florida, Georgia, Maryland, Michigan, New York, Ohio
2026-05-25
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsTremfya·JNJ-78934804·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsZoldonrasib·Leucovorin·Irinotecan·Nab-paclitaxel
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2026-05-22
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641HR+/HER2- Breast Cancer
DrugsBGB-43395·Ribociclib·Abemaciclib·Palbociclib
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois
2026-05-22
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-05-22
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsTremfya·JNJ-78934804·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
NCT07479797Relapsed or Refractory Large B-cell Lymphoma
DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480Myelodysplastic Syndrome, Anemia
DrugsEpoetin Alfa·Elritercept
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana
2026-05-21
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Daratumumab
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2026-05-21
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
DrugsCagriSema·Semaglutide
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078Chronic Graft-versus-host-disease
DrugINCA034176
Incyte Corporation
Phase 2
60
California, District of Columbia, Florida, Georgia, New York, North Carolina, Pennsylvania, Washington
2026-05-20
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650Type 2 Diabetes Mellitus, T2DM
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Maryland, Nebraska, New Jersey, Ohio
2026-05-18
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Georgia, Indiana, Missouri, North Carolina, Texas, Utah, Virginia
2026-05-14
Recruiting
A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers
NCT07598136Smoking, Tobacco
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
NCT07610473Major Depressive Disorder (MDD)
DrugDT-101
Draig Therapeutics Ltd
Phase 2
118
Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
DrugSarilumab
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886Dry Eye Disease (DED)
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
NCT07406360Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399Obesity or Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana
2026-05-11
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York
2026-05-11
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugPF-08653944
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Recruiting
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689Major Depressive Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
NCT07535034Gout
DrugDotinurad
Crystalys Therapeutics
Phase 2
90
Alabama, California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland
2026-05-08
Recruiting
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
NCT07543120Hypertension (HTN)
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
DrugTemozolomide
Black Diamond Therapeutics, Inc.
Phase 2
162
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-05-05
Rows per page Showing 101–200 of 2350
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,350 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,212 of the 2,350 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,038 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.